Pharmaceuticals firm Wockhardt announced Q1FY23 Result : UK Business stood at Rs.196 Cr in Q1FY23 (PY Rs.407 Cr). UK Business contributed about 33% of Global Revenue. India Business: India Business stood at Rs.158 Cr showing a growth of 4% compared to PY. India Business contributed 27% of the Global Revenue. EMROK, the NCE launched during FY21 continues to provide unmatched benefits to the patients. Emerging Markets Business of the Company stood at Rs.117 Cr in Q1FY23 (PY Rs.124 Cr). Emerging Markets Business contributed about 20% of the Global Revenue. Irish Business stood at Rs.37 Cr in Q1FY23 (PY Rs.36 Cr). US Business stood at Rs.74 Cr in Q1FY23 (PY Rs.102 Cr). US Business contributed 12% of the Global Revenue. US business was impacted by price erosion and supply disruptions. Research and Development expenditure during the quarter was at Rs.36 Cr (6% to sales) and including capital expenditure was at 10.7% to sales. Result PDF
Pharmaceuticals firm Wockhardt declares Q4FY22 result: Wockhardt’s FY22 Revenue grew by 17% over FY21. Long Term Debt reduced by Rs 450 Cr. Successful Rights Issue of Rs.748 Cr. The Company recorded a Revenue of Rs.655 Cr registering a growth of 4% compared to previous corresponding quarter and an EBITDA of Rs. (33) Cr compared to Rs. (80) Cr in the corresponding quarter of the previous year. There is Revenue growth of 17% in FY22 over the previous year and substantial improvement in EBITDA at Rs.298 Cr. During the quarter, the company also successfully completed its Rights Issue of Rs. 748 Cr which was fully subscribed. Company used these proceeds to significantly reduce debt and strengthen the balance sheet. Result PDF
Pharmaceuticals company Wockhardt declares Q3FY22 result: Wockhardt’s Q3 FY22 Revenue grew by 12% over Q3 FY21 and EBITDA grew many fold at Rs.114 crore The Company recorded substantial growth in Revenue (up by 12% over previous corresponding quarter) and in EBITDA at Rs.114 crore compared to a profit of Rs.56 crore in the corresponding quarter of the previous year. There is Revenue growth of 21% in 9MFY22 over the previous year and substantial improvement in EBITDA at Rs.331 cr Result PDF